Sequential CAR-T therapy for CD5/CD7 positive T-cell leukemia/lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
- Your cancer did not go away after initial treatment, or it came back after remission.
- Your cancer cells have a protein called CD7 or CD5 on their surface (tested by a lab).
- You are between 2 and 60 years old.
- You are healthy enough to tolerate treatment (no serious heart, lung, liver, kidney problems, active infections, or HIV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are reprogrammed to find and destroy T-cell leukemia or lymphoma cells that have the CD5 protein. It may be an option if your cancer has come back or hasn't responded to other treatments.
This trial tests a new kind of immunotherapy called CD7 CAR-T therapy for people with T-cell cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The CAR-T cells are made from your own immune cells or a donor's, and they are designed to find and destroy cancer cells that carry the CD7 marker.
This trial tests a new type of immune therapy called CAR T cells that are designed to find and attack cancer cells with a CD5 marker. It may be an option for people with T-cell leukemia or lymphoma that has not responded to standard treatments.
This trial tests a new type of immune cell therapy (multi-CAR T cells) designed to target and kill cancer cells that have a marker called CD7. It may help people with certain blood cancers that have not responded well to other treatments.
This trial tests a new immune cell therapy (CAR T-cells) that targets CD5 found on certain T-cell cancers. It may be an option for people whose cancer has not responded to other treatments.
This trial tests a new treatment called CD5 CAR T-cell therapy for people with T-cell lymphoma that has come back or not responded to standard treatments. It offers a possible option when other therapies like chemotherapy or stem cell transplant are no longer working.
Hear when a new T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.